ROS-responsive nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis
Journal of Controlled Release · 2024-10 · 374 · 112-126
DOI: 10.1016/j.jconrel.2024.08.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-10. Verfasst von Qigu Yao und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Ho…. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Chenodeoxycholic Acid, Cholangitis, Sclerosing. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Key Research and Development Program of Zhejiang Province, Fundamental Research Funds for the Central Universities, National Key Research and Development Program of China.
Abstract (Originalsprache)
Primary sclerosing cholangitis (PSC) is a challenging cholestatic liver disease marked by progressive bile duct inflammation and fibrosis that has no FDA-approved therapy. Although obeticholic acid (OCA) has been sanctioned for PSC, its clinical utility in PSC is constrained by its potential hepatotoxicity. Here, we introduce a novel therapeutic construct consisting of OCA encapsulated within a reactive oxygen species (ROS)-responsive, biodegradable polymer, further cloaked with human placenta-derived mesenchymal stem cell (hP-MSC) membrane (MPPFTU@OCA). Using PSC patient-derived organoid models, we assessed its cellular uptake and cytotoxicity. Moreover, using a PSC mouse model induced by 3,5-diethoxycarbonyl-1,4-dihydro-collidine (DDC), we demonstrated that intravenous administration of MPPFTU@OCA not only improved cholestasis via the FXR-SHP pathway but also reduced macrophage infiltration and the accumulation of intracellular ROS, and alleviated mitochondria-induced apoptosis. Finally, we verified the ability of MPPFTU@OCA to inhibit mitochondrial ROS thereby alleviating apoptosis by measuring the mitochondrial adenosine triphosphate (ATP) concentration, ROS levels, and membrane potential (ΔΨm) using H2O2-stimulated PSC-derived organoids. These results illuminate the synergistic benefits of integrating an ROS-responsive biomimetic platform with OCA, offering a promising therapeutic avenue for PSC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd., Hangz…
- MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou City 310058, China; Collaborative Innovation Center for Diagnosis and Tr…
Förderung
- Key Research and Development Program of Zhejiang Province
- Fundamental Research Funds for the Central Universities
- National Key Research and Development Program of China
- National Key Research and Development Program of China Stem Cell and Translational Research
Zitieren
APA
Yao, Q., Wang, B., Yu, J., Pan, Q., Yu, Y., Feng, X., Chen, W., Yang, J., Gao, C., & Cao, H. (2024). ROS-responsive nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis. Journal of Controlled Release, 374, 112-126. https://doi.org/10.1016/j.jconrel.2024.08.006
Vancouver
Yao Q, Wang B, Yu J, Pan Q, Yu Y, Feng X, et al. ROS-responsive nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis. Journal of Controlled Release. 2024;374:112-126. doi:10.1016/j.jconrel.2024.08.006
BibTeX
@article{Yao2024,
author = {Yao, Qigu and Wang, Beiduo and Yu, Jiong and Pan, Qiaoling and Yu, Yingduo and Feng, Xudong and Chen, Wenyi and Yang, Jinfeng and Gao, Changyou and Cao, Hongcui},
title = {ROS-responsive nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis},
journal = {Journal of Controlled Release},
year = {2024},
volume = {374},
pages = {112--126},
doi = {10.1016/j.jconrel.2024.08.006}
}
EUVIMED